Cancer Council Victoria | Victorian Cancer Trials Link

A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 â‰¥ 50%.

Clinical summary

The purpose of this study is to evaluate the efficacy of two immunotherapies, Pumitamig versus Pembrolizumab, in people with previously untreated advanced Non-Small Cell Lung Cancer (NSCLC) with PD-L1 ≥ 50%.
You may be eligible for this study if you have:

NSCLC with Stage IIIB/IIIC or Stage IV disease.
Programmed death ligand-1 (PD-L1) expression ≥ 50%.
Not had prior systemic anti-cancer treatment for locally advanced or metastatic NSCLC. Treatment at an earlier stage of disease may be permitted.

Eligible participants will be randomly assigned (by chance) to receive either Pumitamig or Pembrolizumab.

Conditions

This trial is treating patients with locally advanced or metastatic non-small cell lung cancer

Trial Acronym
ROSETTA Lung-202

Trial Identifiers
NCT07361510
CA266-0002; U1111-1326-9286
2025-523586-18

Cancer
Non-Small Cell Lung Cancer

Age: 18+
Phase: III

For full trial details, visit trials.cancervic.org.au/details/vctl_nct07361510